Clinical trial NCT03471767: AXS-05 Phase II Trial on Smoking Behavior
Official title: A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Smoking Cessation
Smoking, Cigarette
Nicotine Dependence
Keywords: Smoking cessation
Nicotine dependence
Bupropion
DXM
Nicotine addiction
Cigarette smoking
Dextromethorphan
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Axsome Therapeutics, Inc.
First posted: 2018-03-21
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are randomized to either take AXS-05 or BUP SR in parallel for the duration of the study.
Primary purpose: TREATMENT

Brief summary: This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

Detailed description: This study aims to investigate the potential efficacy of a combination of two FDA-approved agents, sustained release (SR) Bupropion (BUP) and immediate release (IR) Dextromethorphan (DXM), for the purpose of smoking cessation treatment. DXM, a widely used over-the-counter cough suppressant, is a nicotine receptor antagonist. In fact, studies by Duke's Center for Smoking Cessation (CSC) have shown that administration of DXM leads to a decrease in self-administration of nicotine in nicotine-dependent rats. DXM, however, has not been studied in humans. DXM, when taken alone, is not expected to be useful for treating nicotine dependence in humans given DXM rapidly metabolizes in humans via CYP2D6. As a result, therapeutic concentrations needed to bind to nicotine receptors are not obtained. Therapeutic concentrations of DXM are required, therefore, to allow DXM to bind to nicotine receptors and act as a nicotine antagonist. In order to attain therapeutic concentrations of DXM a metabolism inhibitor must be introduced. BUP is a well-known FDA approved smoking cessation medication that has been shown to inhibit the metabolism of DXM. When BUP is co-administered with DXM to healthy volunteers, a significant increase in DXM plasma levels is observed.

Currently, Axsome Therapeutics Inc. (Axsome) is developing and testing an oral fixed-dose combination of IR DXM with SR BUP to achieve therapeutic concentrations of DXM. This investigational drug has been named AXS-05. Axsome has found AXS-05 to be generally safe and well-tolerated in three Phase 1 studies. The adverse event profile of AXS-05 was similar to that of BUP alone.

Given the distinct mechanisms by which BUP and DXM interact, it is hoped that combining DXM and BUP will prove more efficacious than either drug administered alone for the purpose of tobacco use treatment in humans.

Eligibility criteria: Key Inclusion Criteria:

1. Age 18 years or above
2. Daily smoker using 10 or more cigarettes per day
3. Willing to be smoke-free for 7 days
4. Is able to provide written informed consent (in English) to participate in the study and able to understand the procedures and study requirements.
5. Is willing to voluntarily sign and date an informed consent form that is approved by an institutional review board before the conduct of any study procedure.

Key Exclusion Criteria:

1. Current use of a smoking cessation medication (e.g. nicotine replacement, Varenicline, bupropion)
2. Current use of tobacco product other than cigarettes (e.g. e-cigarettes, smokeless tobacco)
3. Not pregnant or breastfeeding
4. Contraindication to the use of bupropion.
5. Additional criteria may apply.

Primary outcomes:
measure: Change in Smoking Intensity
timeFrame: Baseline (V1), 3-Week Follow-Up Visit (V4)
measure: Percentage of Participants Who Experienced a More Than 50% Reduction in Expired Carbon Monoxide (CO) Levels
timeFrame: Baseline (V1), 3-Week Follow-Up Visit (V4)
Secondary outcomes:
measure: Change in Smoking Behavior
timeFrame: 3-Week Follow-Up Visit (V4), 4-Week Follow-Up Visit (V5)
measure: Medication Adherence
timeFrame: Baseline (V1), 3-Week Follow-Up Visit (V4)
measure: Medication Tolerance by Self-Reported Side Effects
timeFrame: Baseline (V1), 3-Week Follow-Up Visit (V4)
measure: Medication Tolerance by Serious Adverse Events
timeFrame: Baseline (V1), 4-Week Follow-Up Visit (V5)
measure: Urinary Levels of Dextromethorphan
timeFrame: 3-Week Follow-Up Visit (V4)
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Center for Smoking Cessation
state: North Carolina
Study officials:
affiliation: Duke Cancer Institute
name: James M Davis, MD
role: PRINCIPAL_INVESTIGATOR
References: